Abstract Germline mutations in the tumor suppressor gene TP53 occur in the majority of families with Li-Fraumeni syndrome, who are at an increased risk for a wide spectrum of early onset cancers. Several genetic polymorphisms in TP53 modify its effect on cancer risk. While some studies indicate that the TP53 PIN3 deletion allele (D) accelerate tumor onset in carriers with TP53 germline mutations, other studies have shown that the TP53 PIN3 insertion allele (I) confers a significantly higher risk of developing cancer than D allele. To further determine the effects of the TP53 PIN3 polymorphism on cancer development among TP53 germline mutations and to evaluate if those are differenence between male and female carriers, we studied a total of 152 germline mutation carriers with available DNA samples that can be used for genotyping. Our results indicate that the TP53 PIN3 polymorphism has a sex-specific effect on the risk of cancer in TP53 mutation carriers, conferring cancer risk in men (P = 0.0041) but not women with DI or II genotypes.
Introduction
Germline mutations in the TP53 tumor suppressor gene occur in the majority of families with Li-Fraumeni syndrome (LFS) who are at an increased risk for a wide spectrum of early onset cancers (Garber et al. 1991; Kleihues et al. 1997; Nichols et al. 2001) . The polymorphic MDM2 SNP309 G allele is strongly related to early cancer development in LFS kindreds (Bougeard et al. 2006; Marcel et al. 2009 ) and to accelerated tumor formation in a sex-specific fashion (Bond et al. 2006; Fang et al. 2010 ). TP53 polymorphisms have been shown to modify the function of TP53 on cancer risk, with several of them reported to increase cancer susceptibility. Some case-only studies have found that the TP53 codon 72 R allele results in the first tumor onset at an earlier age in carriers of germline TP53 mutations (Bougeard et al. 2006; Marcel et al. 2009 ) while other experimental and cohort studies have provided evidence that the PP genotype for codon 72 increases the risk of cancer (Dumont et al. 2003; Fang et al. 2010; Martin et al. 2003) . Among patients genotyped for the TP53PIN3 polymorphism, which consists of a 16-bp duplication in intron 3, the mean age at first cancer diagnosis was found to be 19 years younger in carriers of the nonduplicated allele (A1) than in carriers of the duplicated allele (A2) (Marcel et al. 2009 ). Elsewhere the nonduplicated allele A1 is referred to as deletion allele (D) and the duplicated allele A2 is referred to as insertion allele (I). However, a meta-analysis of 26 population-based casecontrol studies showed that the insertion allele (I) conferred a significantly elevated risk of cancer development (those heterozygous for deletion/insertion and homozygous for insertion [DI ? II] versus those homozygous for deletion [DD] , odds ratio = 1.14 with 95% confidence interval [CI] = 1.02-1.27) (Hu et al. 2010) . To further verify the relative risk of cancer in TP53 germline mutation carriers with TP53 PIN3 polymorphisms, we performed the present study in a cohort of families with LFS and LFS-like diseases. We also evaluated the sex-specific effect of this polymorphism on cancer susceptibility.
Patients and methods

Study population
The present study population consisted of several cohorts of families identified through patients with early onset sarcoma or multiple cancers. Details about the recruitment of these families were provided in a previous study by our group (Fang et al. 2010) . A total of 213 germline mutation carriers were available for study, of whom 152 had DNA samples available for genotyping TP53 PIN3. These 152 individuals were 47.4% male, 4.1% black, 73.0% white, and 73.7% having at least one tumor. There was no characteristic difference between genotyped and non-genotyped individuals (P = 0.9818 for sex and 0.1612 for race, respectively), but the non-genotyped group had higher rate of cancer development (P = 0.0028) (Table S1 ). In addition, we genotyped TP53 PIN3 for 399 individuals with wild-type TP53 (N = 257), unknown TP53 status (N = 133) or genotype controls (N = 9). TP53 unknown status means that these samples were not sequenced and their status could not be inferred from the pedigree (not obligate carriers). These nine observations were excluded because they were used as a genotype quality control. The results were 100% concordant. Among 257 wild-type TP53 mutation carriers, 43.2% were males, 12.8% black, 70.4% white, 15.5% having at least one tumor and 239 with complete follow-up information (data not shown here). Genotyping was done by fluorescent capillary electrophoresis on an Applied Biosystems 3100 Genetic Analyzer. Amplification was done by a three primer reaction using a FAM-labeled Universal primer (5 0 GGGACACCGCTGAT CGTTTA) as described in Bachinski et al. (2003) . Forward primer (5 0 GACGGGACACCGCTGATCGTTTACTGAA AACAACGTTCTG-GTA) and reverse primer (5 0 AAGG GGGACTGTAGATGGGTG) amplified fragments of 141 and 157 bp. We observed these 152 individuals for their onsets of any type of cancer and determined the effect on cancer risk of this polymorphism.
Statistical analysis
We first stratified our cancer patients with TP53 mutations byTP53 PIN3 genotype and tested for differences in age at cancer diagnosis among the different PIN3 genotype groups using a nonparametric Kruskal-Wallis test. The time to onset was from birth to first cancer diagnosis, for those who had cancer, and the censoring time was from birth to last contact (fixed to 31 December 2001), death, or study termination, for those who had no cancer. Among these carriers of germline TP53 mutations, we performed a log-rank test to quantify differences in cancer risk by genotype using the Kaplan-Meier product-limit method. To adjust for correlation within families, we further modeled the relative risk of these polymorphisms in LFS patients using a weighted Cox proportional hazard model. We took into consideration the familial correlation in the model by calculating the robust variance. This model allowed us to adjust (or not adjust) for sex, race, birth year, and having TP53 codon 72 polymorphism. To identify the haplotypes defined by the two TP53 polymorphisms, we extracted all TP53-positive pedigrees in which there was one TP53 mutation carrier and at least one family member's genotypes for both TP53 PIN3 and TP53 codon 72 were known. We applied a Monte Carlo-based method using the SimWalk2 software program to specify the haplotypes for these polymorphisms (Weeks et al. 1995) . All statistical analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC). P \ 0.05 was considered statistically significant.
Results
Of these 152 carriers with a TP53 germline mutation, 112 (73.7%) had cancer, and their median age at cancer diagnosis or censoring was 26.9 years (mean ± standard deviation: 27.5 ± 18.3). The average age at first cancer diagnosis in those with (DD) genotypes did not differ significantly from the average age in those with (DI ? II) genotypes among patients with mutant TP53 (21.1 versus 24.0 years, P = 0.4847; Table 1 ). Furthermore, the distribution of the types of cancers (epithelial cancer, hematopoetic cancer, and sarcoma) did not differ significantly between the DD and DI ? II groups using the Fisher exact test (P = 0.300; Table S2 ). We also tested for differences in age at cancer diagnosis by PIN3 polymorphisms among affected wild-type TP53 carriers and found no significant results (51.0 vs. 39.5 years, P = 0.2546; Table 1 ).
Next, we examined the time to first cancer onset in each group. A total of 32.8% of mutation carriers with DD genotypes failed to develop cancer, whereas only 3.0% of mutation carriers with DI ? II genotypes were free of cancer during the follow-up time. Among these carriers of germline TP53 mutations, we performed a log-rank test to quantify differences in cancer risk by gender and genotype using the Kaplan-Meier product-limit method. The mean age of cancer diagnosis estimated using Kaplan-meier method was 28 and 35 years in females and males, respectively. Long-rank test showed no difference for the mean age of tumor onset between females and males in 152 TP53 germline mutation carriers with available DNA data (P = 0.1160) (Table S3 ) which seems non-concordant with the previous report (Fang et al. 2010) in total 213 germline mutation carriers, among which significant difference for the mean age of tumor onset between females and males was found (P = 0.0057). The inconsistence occurs due to non-random selection of DNA sample for genotyping. Those 152 TP53 germline mutation carriers that were genotyped for PIN3 had lower rate of cancer patients (73.7%) than those 61 TP53 mutation carriers that were not genotyped for PIN3 (91.8%) (Table S1 ). We found a significant difference in risk of cancer between the DD and DI ? II genotypes (P = 0.0154; Fig. 1 ). The findings regarding the effect of TP53 PIN3 polymorphism from the present cohort study were more reliable than those from the above case-only studies because in the cohort study we prospectively observed the effects of PIN3 polymorphisms on cancer risk. Our stratification analyses showed that male DI ? II carriers had poorer disease-free survival rates than did male DD carriers (P = 0.0358; Fig. 2 ) whereas women in both genotype groups had the same survival rates over time (P = 0.2654; Fig. 3 ).
In the Kaplan-Meier method, we treated all individuals as being unrelated and did not estimate the effect size (hazard ratio) of the polymorphisms. In the further Cox proportional hazard model, while considering the correlation within families and adjusting for race and birth year, female had earlier age of tumor diagnosis than male without stratification byTP53 PIN3 (hazard ratio [HR] = 1.43, 95% CI 1.05-1.95) or within TP53 PIN3 DD group (HR = 1.59, 95% CI 1.08-2.34) (Table S3) . A significant risk effect on onset of tumor was noted with the TP53 PIN3 DI/II genotype in the univariate analysis (HR = 1.66, 95% (Table 2 and  Table S4 ). These results thus indicate that the TP53 PIN3 DI/II genotype has a sex-specific risk effect against cancer development in men. A previous study by our group showed that the TP53 codon 72 PP homozygosity was a risk factor for cancer in TP53 mutation carriers; this effect was significant in men but not women (Fang et al. 2010) . The TP53 PIN3 polymorphism is located just 181 bp downstream from the TP53 codon 72 variant. To allow for linkage disequilibrium between TP53 PIN3 and TP53 codon 72 (r 2 = 0.61 and D 0 = 0.90 in our data), we included both TP53 PIN3 and TP53 codon 72 polymorphisms in our model and found that the effect of TP53 PIN3 DI/II genotypes remained significant in men when controlling for codon 72 polymorphisms (HR = 1.72, 95% CI = 1.05-2.84; Table 2  and Table S5 ) whereas codon 72 was not significant when controlling for PIN3 polymorphisms (HR for codon 72 PP = 1.89, 95% CI 0.85-4.21; Table S5 ), suggesting that the TP53 PIN3 variant has an independent effect on cancer risk in men with TP53 mutation.
We identified the haplotypes defined by the two TP53 polymorphisms and evaluated their effects on cancer risk. As with the D-R haplotype (D allele at TP53 PIN3 and R allele at codon72), the D-P haplotype had a significant risk effect on cancer risk in men carrying TP53 mutants (HR = 1.78, 95% CI 1.18-2.70) but not women with it (HR = 1.20, 95% CI 0.57-2.59) ( Table 2 and Table S6 ), whereas the I-P haplotype had a non-significant risk effect on cancer risk in males carrying TP53 mutants when compared with the D-R haplotype (HR = 1.32, 95% CI 0.80-2.17; Table S6 ). The results of this haplotype analysis are consistent with those of our previous study in which the TP53 codon 72 P allele increased the risk of cancer in men but not women (Fang et al. 2010) . We also estimated the effect size of the TP53 PIN3 DI/II genotype in wild-type TP53 carriers and found no significant results among all (HR = 0.63, 95%CI 0.28-1.42), among males (HR = 0.79, 95%CI 0.28-2.21) or among females (HR = 0.63, 95%CI 0.20-1.95) ( Table S7 ). Our results suggest that TP53 PIN3 polymorphism only modifies the effect of mutant TP53 on cancer risk.
Discussion
In this study, we identified the effect of TP53 PIN3 polymorphism on tumor onset in a cohort of TP53 germline mutation carriers. We found that TP53 PIN3 DI/II genotypes increased cancer risk in men but not women. Although Marcel et al. reported that TP53 PIN3 A1(D) allele was associated with an earlier tumor onset of 19 years in mutation carriers with LFS or LFS-like syndrome (Marcel et al. 2009 ), we found no significant difference in age at first cancer diagnosis between TP53 PIN3 deletion and insertion polymorphisms in affected mutation carriers. Nevertheless, when we observed all mutation carriers (cancer and non-cancer) during the follow-up period of time, we found that the log rank test results and Cox regression model agreed that the TP53 PIN3 DI/II genotype had an increased risk effect on cancer development, which was significant in men but not women. Our findings were consistent with the meta-analysis reports by Hu et al. (2010) regarding the risk effect of the insertion allele on any type of cancer development. But we did not observe a significant effect of DI/II on breast cancer development (P = 0.8459) which was inconsistent with the combined analysis by Hu et al. The effect of the A2 variant in men was independent of the presence of TP53 72P allele. Considering the linkage disequilibrium between TP53 PIN3 and TP53 codon 72 polymorphisms, the D-P haplotype had a significantly higher risk effect on cancer than did the D-R haplotype in men. Dumont et al. (2003) reported that the TP53 72R variant was 5-to 10-times more likely to induce programmed cell death than the 72P variant, and the authors suggested that the low apoptotic potential of the 72P variant might account for increased predisposition to cancer development in carriers of the 72P variant. However, the functional basis for the risk effect of TP53 PIN3 remains to be unclear. Gemignani et al. (2004) found that the presence of the A2 (I) allele was associated with an elevated risk of colorectal cancer and with the reduced levels of TP53 messenger RNA expression in lymphoblastoid cells. A possible explanation for this finding is a reduced stability of the pre-messenger RNA carrying the 16-bp insertion in intron 3 of the tumor suppressor gene TP53. Marcel et al. (2010) demonstrated that the formation of G-quadruplex structures (G4) in a GC-rich region of intron 3 that modulates the splicing of intron 2, thus resulting in differential expression of transcripts encoding distinct p53 isoforms. Our findings were inconsistent with Marcel et al. (2009) in terms of the effect of TP53 PIN3, due to limited sample size in both studies or different study design between them. More observations are needed to better examine the relationship between TP53 PIN3 polymorphisms and cancer risk.
In summary, our results show that TP53 PIN3 polymorphisms have a sex-specific effect on the risk of cancer in TP53 mutation carriers, conferring increased cancer risk in men but not women with DI/II genotypes. However, the biologic mechanisms of this effect of TP53 PIN3 polymorphisms in men only remain to be elucidated. Our results also suggest that females generally have higher cancer risk than males in mutant TP53 carriers.
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